{"version":"1.0","type":"link","title":"Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study.","author_name":"Kersten MJ 외","author_url":"https://prs-insight.online/author/Kersten%20MJ","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/158563","thumbnail_width":1200,"thumbnail_height":630}